Chronic lymphocytic leukemia (CLL) is the most common leukemia, primarily affecting older patients and characterized by a variable clinical course due to specific genomic alterations. Diagnosis involves blood tests and immunophenotyping, while prognosis is assessed using staging systems and genetic markers. Treatment is reserved for symptomatic or advanced cases, with various targeted therapies available, though challenges remain in managing patients resistant to current treatments.